Business Wire

ORAL-B

Share
New Award Programme From Oral-B and the International Association for Disability and Oral Health (iADH) Champions Disability Positive Dental Practices Across Europe

Today, on Global Accessibility Awareness Day (GAAD), Oral-B proudly launches the Disability Champions Award Programme as part of its ongoing mission to make oral care more accessible to everybody. In partnership with the iADH, the programme aims to make the dentist office experience across Europe more inclusive and positive for those with disabilities and their caregivers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515281762/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Benjamin Binot, P&G Europe Oral Care Senior Vice President, announcing the launch of the Disability Champions Awards Programme and previewing the new iO2 toothbrush at Oral-B’s ‘Championing the Perfect Clean for All’ event in Amsterdam. (Photo: Business Wire)

Over a third (36%) of people with visible and non-visible disabilities feel anxious or frustrated when it comes to visiting the dentist. For instance, individuals with Autism Spectrum Disorder may experience heightened anxiety in unfamiliar environments such as a dental practice, as it disrupts their normal routine. Similarly, a patient with Cerebral Palsy, who may face motor challenges without intellectual disability, might find it difficult to brush their teeth effectively due to limitations in fine motor coordination.

To help overcome this, the Disability Champions Award Programme encourages one member of each dental practice across Europe to become the personal lead to ensure their practice is committed to be more disability positive – because sometimes all it takes is one person to truly make a difference.

By completing the necessary online training and accessibility suggestions devised by iADH and Oral-B (available at https://www.iadh.org/oral-b-iadh-disability-champions/) dental staff who meet the requirements will earn their Disability Champions award. They receive a badge that can be used within their office or on social media to encourage others to become Disability Champions. Their practice will also be visible on Oral-B’s website to make it easier for people with disabilities and their caregivers to find disability positive dental practices near them, and to feel more confident and encouraged about visiting the dentist.

Benjamin Binot, P&G Europe Oral Care Senior Vice President, said: “Last year, we launched The Big Rethink initiative in partnership with iADH to rethink how Oral-B can make oral care more inclusive, accessible, and positive for people with disabilities, their caregivers, and everyone in between. This year, we are making our intention good by driving action amongst dental practitioners with the Disability Champions Awards Programme. With our long-term partners, the iADH, we have devised a programme that is straightforward for dental staff to undertake and promote, and that demonstrates their commitment to raising the standard of oral care for people with disabilities.”

Professor. Pedro Diz Dios, President Elect of iADH, said: “At the iADH, we are about promoting equitable oral care. However, we often find that dental practitioners have pre-conceived notions of what makes their practice inclusive, accessible, and positive for people with disabilities and their caregivers. We want to help dentists rethink how to provide a better service for all and believe that appointing one person in the organization to become a Disability Champion will help drive the right change forward. The hope is that as many dental practices as possible across Europe take part in the Disability Champions Award Programme and make better oral care for all a reality.”

The Disability Champions Awards Programme is being launched at Oral-B’s ‘Championing the Perfect Clean for All’ global event being held in Amsterdam between 15-16th May. Over 100+ media, dental professionals and people with disabilities will learn more about the programme, hear inspiring stories from the latest Disability Champions, and experience first-hand how Oral-B plans to bring a better oral care experience to people with disabilities - at the dentist practice and at home. Indeed, Oral-B is previewing its new Oral-B iO2 toothbrush that will bring its revolutionary iO technology to a wider audience, including people with disabilities.

The iO2 is crafted to effortlessly transition manual toothbrush users to electric toothbrushes by bringing Oral-B’s iO technology to life with one simple touch for a simpler, more intuitive cleaning experience that’s tough on plaque and gentle on gums! The dentist-inspired round brush head surrounds teeth, perfectly adapting to their unique shape, removing 100% more bacterial plaque than regular manual brushes even in hard-to-reach areas of the mouth. The iO2 will also come with a new brush head with Smart Bristles that now fully fade their colour to white, making it easy to know when it's time to change your brush head.

1 The Oral Health & Disability European Study (2022) surveyed 5,000 respondents across UK, France, Germany and Italy

Notes to editor:

  • About the research: The Oral Health & Disability European Study (2022) surveyed 5,000 respondents across UK, France, Germany and Italy, and was conducted by Reputation Leaders on behalf of Oral-B
  • For more information on The Disability Champions Awards Programme, please visit here. The website offers relevant and helpful content for people with disabilities, their caregivers, and families, as well as the professional community.
  • Please contact your local Oral-B press office for more information and on local availability of iO2

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bold®, Braun®, Daz®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Herbal Essences®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, Tampax®, Venus® and Vicks®.

Although headquartered in the US, P&G was founded by an Englishman and an Irishman in 1837, our heritage lives on through the work of Research & Development Centres, Manufacturing Plants and Business sites, across the UK & Ireland.

Beyond our Purpose, Values & Principles, the foundation on which P&G was built and our guiding force for over 180 years, we aspire to be a force for growth so that we can be a force for growth in the communities in which we live and work. Through our citizenship priorities, we want to build a better world for all of us - inside and outside of P&G - free from gender bias, with equal voice and equal representation. Environmental sustainability is embedded into our business, and has been for decades, and we have a strong track record of delivering on our goals in this area. We support communities around the world through our people, our brands and our partners by delivering the comforts of home, health and hygiene.

About Oral-B

Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About the International Association for Disability and Oral Health (iADH)

The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, research, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515281762/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil

SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release

IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S

New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release

Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers

Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release

Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye